Overview
CRISPR Therapeutics AG, based in Switzerland, operates within the biotechnology industry, primarily focusing on the development of gene-based medicine leveraging the CRISPR/Cas9 gene-editing platform. The company has ventured into strategic collaborations to enhance the breadth of its therapeutic programs, notably in areas such as immuno-oncology and rare diseases. A signature project includes its partnership with Vertex Pharmaceuticals, aimed at advancing CTX001, a therapy for the treatment of transfusion-dependent beta-thalassemia and severe sickle cell disease. CRISPR Therapeutics' approach emphasizes transformative gene-editing therapies that position it at the forefront of genetic medicine, aiming to provide substantial solutions for previously intractable diseases through direct genetic modification.
Basic Stats
The Factor Analysis chart (below right) shows a view of CRISPR Therapeutics AG from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 88.38 MM |
| Earnings Date | |
| EPS (TTM) | -5.29 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | -0.20 |
| ROE | -0.24 |
| ROIC | -0.24 |
| CROIC | -0.15 |
| OCROIC | -0.17 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 67.48 /100 |
| Profitability | 9.20 /100 |
| Quality Score | 23.92 /100 |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | 84.60 /100 |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for CRISPR Therapeutics AG is US$80.81. The forecasts range from a low of US$32.22 to a high of US$280.54. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for CRISPR Therapeutics AG. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2024-06-27 | Needham | Buy | Buy | Reiterate |
| 2024-06-17 | Piper Sandler | Overweight | Overweight | Reiterate |
| 2024-06-17 | Needham | Buy | Buy | Reiterate |
| 2024-05-23 | Citigroup | Buy | Buy | Maintains |
| 2024-05-10 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-05-09 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-05-09 | Cantor Fitzgerald | Neutral | Reiterate | |
| 2024-05-09 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2024-05-09 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-05-09 | Needham | Buy | Buy | Maintains |
| 2024-05-09 | Baird | Neutral | Neutral | Maintains |
| 2024-04-18 | Citigroup | Buy | Buy | Maintains |
| 2024-04-11 | Needham | Buy | Buy | Reiterate |
| 2024-03-06 | Mizuho | Buy | Buy | Maintains |
| 2024-02-26 | Morgan Stanley | Underweight | Underweight | Maintains |
| 2024-02-22 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-02-22 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2024-02-22 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2024-02-22 | Chardan Capital | Buy | Buy | Maintains |
| 2024-02-21 | Needham | Buy | Buy | Maintains |
| 2024-02-15 | Wolfe Research | Peer Perform | Initiate | |
| 2023-12-11 | Truist Securities | Buy | Buy | Maintains |
| 2023-12-11 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2023-12-11 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2023-12-11 | TD Cowen | Market Perform | Underperform | Downgrade |
| 2023-12-11 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2023-12-11 | Needham | Buy | Buy | Maintains |
| 2023-12-08 | Mizuho | Buy | Buy | Reiterate |
| 2023-12-08 | Truist Securities | Buy | Buy | Reiterate |
| 2023-12-05 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2023-11-13 | Morgan Stanley | Underweight | Underweight | Maintains |
| 2023-11-07 | Needham | Buy | Buy | Maintains |
| 2023-11-07 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2023-11-01 | Needham | Buy | Buy | Reiterate |
| 2023-10-30 | Needham | Buy | Buy | Reiterate |
| 2023-10-17 | Cantor Fitzgerald | Overweight | Neutral | Downgrade |
| 2023-09-27 | Mizuho | Buy | Initiate | |
| 2023-08-18 | Citigroup | Neutral | Buy | Upgrade |
| 2023-08-17 | Citigroup | Neutral | Buy | Upgrade |
| 2023-08-14 | Morgan Stanley | Underweight | Underweight | Maintains |
| 2023-08-10 | Oppenheimer | Outperform | Outperform | Reiterate |
| 2023-08-08 | Credit Suisse | Neutral | Neutral | Maintains |
| 2023-08-08 | EF Hutton | Buy | Buy | Reiterate |
| 2023-08-08 | Needham | Buy | Buy | Reiterate |
| 2023-08-08 | Chardan Capital | Buy | Buy | Maintains |
| 2023-07-25 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2023-06-09 | EF Hutton | Buy | Reiterate | |
| 2023-06-09 | JMP Securities | Market Outperform | Maintains | |
| 2023-06-09 | Needham | Buy | Buy | Reiterate |
| 2023-06-01 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2023-05-30 | William Blair | Outperform | Reiterate | |
| 2023-05-23 | Citigroup | Neutral | Neutral | Maintains |
| 2023-05-12 | Morgan Stanley | Underweight | Underweight | Maintains |
| 2023-05-09 | RBC Capital | Sector Perform | Reiterate | |
| 2023-05-09 | JMP Securities | Market Outperform | Reiterate | |
| 2023-05-09 | Credit Suisse | Neutral | Maintains | |
| 2023-05-09 | Stifel | Hold | Maintains | |
| 2023-05-09 | Needham | Buy | Reiterate | |
| 2023-04-20 | Needham | Buy | Reiterate | |
| 2023-04-17 | JMP Securities | Market Outperform | Reiterate | |
| 2023-04-17 | EF Hutton | Buy | Reiterate | |
| 2023-04-13 | Cantor Fitzgerald | Overweight | Initiate | |
| 2023-04-03 | EF Hutton | Buy | Reiterate | |
| 2023-03-21 | Bernstein | Market Perform | Initiate | |
| 2023-03-07 | Baird | Neutral | Initiate | |
| 2023-02-27 | Morgan Stanley | Underweight | Maintains | |
| 2023-02-27 | JMP Securities | Market Outperform | Reiterate | |
| 2023-02-23 | Oppenheimer | Outperform | Maintains | |
| 2023-02-22 | Chardan Capital | Buy | Maintains | |
| 2023-02-22 | Credit Suisse | Neutral | Maintains | |
| 2023-02-22 | EF Hutton | Buy | Reiterate | |
| 2023-02-22 | Needham | Buy | Maintains | |
| 2023-01-19 | JMP Securities | Market Outperform | Maintains | |
| 2023-01-05 | EF Hutton | Buy | Initiate | |
| 2022-11-23 | Citigroup | Neutral | Maintains | |
| 2022-11-07 | SVB Leerink | Outperform | Maintains | |
| 2022-11-02 | RBC Capital | Sector Perform | Maintains | |
| 2022-11-02 | Credit Suisse | Neutral | Maintains | |
| 2022-10-11 | Morgan Stanley | Underweight | Initiate | |
| 2022-08-09 | Credit Suisse | Neutral | Maintains | |
| 2022-08-09 | RBC Capital | Sector Perform | Maintains | |
| 2022-08-09 | Chardan Capital | Buy | Maintains | |
| 2022-08-09 | Barclays | Overweight | Equal-Weight | Downgrade |
| 2022-08-08 | SVB Leerink | Outperform | Maintains | |
| 2022-08-02 | Citigroup | Neutral | Maintains | |
| 2022-06-23 | Evercore ISI Group | Outperform | In-Line | Downgrade |
| 2022-06-23 | Oppenheimer | Outperform | Maintains | |
| 2022-06-22 | Chardan Capital | Buy | Maintains | |
| 2022-06-22 | Stifel | Hold | Maintains | |
| 2022-06-22 | Piper Sandler | Overweight | Maintains | |
| 2022-06-17 | BMO Capital | Outperform | Initiate | |
| 2022-06-13 | Stifel | Hold | Maintains | |
| 2022-05-24 | Goldman Sachs | Neutral | Maintains | |
| 2022-05-23 | Piper Sandler | Overweight | Maintains | |
| 2022-05-17 | Citigroup | Neutral | Maintains | |
| 2022-05-13 | Needham | Buy | Maintains | |
| 2022-05-11 | Goldman Sachs | Neutral | Maintains | |
| 2022-05-11 | Oppenheimer | Outperform | Maintains | |
| 2022-05-11 | JMP Securities | Market Outperform | Maintains | |
| 2022-05-10 | Barclays | Overweight | Maintains | |
| 2022-05-10 | RBC Capital | Sector Perform | Maintains | |
| 2022-05-10 | Chardan Capital | Buy | Maintains | |
| 2022-05-10 | SVB Leerink | Outperform | Maintains | |
| 2022-04-28 | Credit Suisse | Neutral | Initiate | |
| 2022-03-15 | Citigroup | Neutral | Maintains | |
| 2022-02-16 | RBC Capital | Sector Perform | Maintains | |
| 2022-02-16 | SVB Leerink | Outperform | Maintains | |
| 2021-12-07 | Cowen & Co. | Market Perform | Initiate | |
| 2021-11-04 | Barclays | Overweight | Maintains | |
| 2021-10-19 | SVB Leerink | Outperform | Initiate | |
| 2021-10-13 | Stifel | Hold | Maintains | |
| 2021-08-16 | Canaccord Genuity | Buy | Maintains | |
| 2021-07-30 | Chardan Capital | Buy | Maintains | |
| 2021-06-14 | Citigroup | Sell | Neutral | Upgrade |
| 2021-04-21 | Barclays | Overweight | Maintains | |
| 2021-04-21 | Jefferies | Hold | Buy | Upgrade |
| 2021-03-04 | JMP Securities | Outperform | Initiate | |
| 2021-03-01 | Barclays | Overweight | Maintains | |
| 2021-02-17 | Oppenheimer | Outperform | Maintains | |
| 2020-12-10 | Chardan Capital | Buy | Maintains | |
| 2020-12-10 | Needham | Buy | Maintains | |
| 2020-12-07 | Roth Capital | Buy | Maintains | |
| 2020-12-07 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
| 2020-10-29 | Piper Sandler | Overweight | Maintains | |
| 2020-10-23 | RBC Capital | Sector Perform | Initiate | |
| 2020-10-22 | Chardan Capital | Buy | Maintains | |
| 2020-10-05 | B of A Securities | Buy | Initiate | |
| 2020-07-28 | Barclays | Overweight | Maintains | |
| 2020-07-28 | Chardan Capital | Buy | Maintains | |
| 2020-07-28 | Needham | Buy | Maintains | |
| 2020-07-14 | SunTrust Robinson Humphrey | Buy | Initiate | |
| 2020-06-15 | Canaccord Genuity | Buy | Maintains | |
| 2020-03-05 | Stifel Nicolaus | Hold | Initiate | |
| 2020-03-04 | Citigroup | Sell | Maintains | |
| 2020-02-03 | Evercore ISI Group | Outperform | In-Line | Downgrade |
| 2019-11-26 | Oppenheimer | Outperform | Maintains | |
| 2019-11-12 | Oppenheimer | Perform | Outperform | Upgrade |
| 2019-08-01 | Jefferies | Buy | Initiate | |
| 2019-07-26 | Canaccord Genuity | Buy | Initiate | |
| 2019-06-10 | Roth Capital | Buy | Initiate | |
| 2019-04-12 | Evercore ISI Group | Outperform | Initiate | |
| 2019-03-14 | William Blair | Market Perform | Initiate | |
| 2019-02-08 | BTIG Research | Buy | Initiate | |
| 2019-01-28 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2019-01-22 | Citigroup | Neutral | Sell | Downgrade |
| 2018-11-30 | Needham | Buy | Initiate | |
| 2018-10-10 | Wells Fargo | Outperform | Initiate | |
| 2018-09-21 | Raymond James | Underperform | Initiate | |
| 2018-08-24 | Citigroup | Neutral | Neutral | Maintains |
| 2018-04-06 | Goldman Sachs | Buy | Initiate | |
| 2018-03-08 | JMP Securities | Market Outperform | Initiate | |
| 2018-03-07 | Barclays | Overweight | Overweight | Maintains |
| 2018-02-28 | Citigroup | Neutral | Neutral | Maintains |
| 2018-01-23 | SunTrust Robinson Humphrey | Hold | Buy | Upgrade |
| 2017-07-18 | Oppenheimer | Perform | Initiate | |
| 2017-07-14 | SunTrust Robinson Humphrey | Hold | Initiate | |
| 2017-03-28 | Chardan Capital | Buy | Initiate | |
| 2016-11-15 | Citigroup | Neutral | Initiate | |
| 2016-11-14 | PiperJaffray | Overweight | Initiate | |
| 2016-11-14 | Barclays | Overweight | Initiate | |
| 2016-11-14 | Guggenheim | Buy | Initiate | |
| 2024-12-20 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-02-03 | HC Wainwright & Co. | Buy | Initiate | |
| 2024-08-06 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2024-08-06 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-08-06 | Stifel | Hold | Hold | Maintains |
| 2024-08-06 | Chardan Capital | Buy | Buy | Maintains |
| 2024-08-06 | Needham | Buy | Buy | Maintains |
| 2025-07-22 | B of A Securities | Buy | Buy | Maintains |
| 2025-02-12 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2025-02-12 | Truist Securities | Buy | Buy | Maintains |
| 2025-02-12 | Needham | Buy | Buy | Reiterate |
| 2025-02-12 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2025-08-07 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-02-13 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-02-13 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2025-02-13 | Stifel | Hold | Hold | Maintains |
| 2025-02-13 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-13 | Chardan Capital | Buy | Buy | Maintains |
| 2024-11-06 | RBC Capital | Sector Perform | Sector Perform | Reiterate |
| 2024-11-06 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-11-06 | Needham | Buy | Buy | Reiterate |
| 2025-02-19 | Cantor Fitzgerald | Neutral | Neutral | Reiterate |
| 2025-02-14 | Morgan Stanley | Underweight | Underweight | Maintains |
| 2025-02-14 | Evercore ISI Group | In-Line | Outperform | Upgrade |
| 2024-08-08 | Cantor Fitzgerald | Neutral | Reiterate | |
| 2025-05-21 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-05-20 | Needham | Buy | Buy | Reiterate |
| 2024-10-04 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2025-01-07 | B of A Securities | Buy | Buy | Maintains |
| 2025-05-09 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-08-12 | Truist Securities | Buy | Buy | Maintains |
| 2024-12-10 | Chardan Capital | Buy | Buy | Maintains |
| 2025-05-07 | Needham | Buy | Buy | Maintains |
| 2025-05-07 | Chardan Capital | Buy | Buy | Maintains |
| 2025-08-05 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2025-01-14 | Needham | Buy | Buy | Reiterate |
| 2025-02-18 | Citigroup | Buy | Buy | Maintains |
| 2025-04-09 | Needham | Buy | Buy | Reiterate |
| 2025-06-27 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-06-27 | Piper Sandler | Overweight | Overweight | Reiterate |
| 2025-06-27 | Clear Street | Buy | Hold | Downgrade |
| 2025-06-27 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-05-20 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-08-06 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2025-08-05 | Chardan Capital | Buy | Buy | Maintains |
| 2025-06-26 | Chardan Capital | Buy | Buy | Maintains |
| 2025-06-26 | Needham | Buy | Buy | Reiterate |
| 2025-05-08 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2025-07-08 | Needham | Buy | Buy | Reiterate |
